Medicine and Dentistry
Acute Myeloid Leukemia
91%
Overall Survival
48%
Myelodysplastic Syndrome
29%
Hematopoietic Stem Cell
29%
Decitabine
28%
Lenalidomide
25%
Autologous Stem Cell Transplantation
25%
Cell Transplantation
24%
Diffuse Large B-Cell Lymphoma
20%
Hematopoiesis
20%
Hazard Ratio
18%
Neoplasm
17%
Rituximab
17%
Myelodysplastic Syndrome
16%
Azacitidine
16%
Acute Myelogenous Leukemia
14%
Cohort Analysis
14%
Arm
14%
Cancer Cell
14%
Leukemia
12%
Peripheral T-Cell Lymphoma
11%
Phagocytosis
11%
Angioimmunoblastic T-Cell Lymphoma
11%
In Vitro
11%
Positron Emission Tomography-Computed Tomography
10%
Platelet
10%
Population
10%
Posttransplant Lymphoproliferative Disease
10%
Quality of Life
10%
T Cell
9%
Disease
9%
Gene Expression Profiling
9%
Anemia
9%
Progression Free Survival
8%
Leukemia Cell
8%
Hematopoietic Stem Cell
8%
Malignant Neoplasm
7%
Cancer Registry
7%
Programmed Cell Death
7%
Multiple Myeloma
7%
Mitochondrial Respiration
7%
Induction Chemotherapy
7%
Myeloid Malignancy
7%
Clinical Trial
6%
Pemphigus vulgaris
6%
Autophagy
6%
Core Binding Factor
6%
Hypomethylating Agent
6%
Graft Versus Host Reaction
6%
Macrophage
6%
Immunology and Microbiology
Myeloid
100%
Hematopoietic Cell
33%
B Cell
29%
T Cell
27%
Overall Survival
26%
Cell Transplantation
23%
CD47
22%
Hematopoiesis
20%
CD34
20%
Phagocytosis
17%
Cancer Cell
17%
Autologous Stem Cell Transplantation
15%
Macrophage
15%
Rituximab
15%
Population
13%
Stem Cell
13%
Arm
11%
Antineoplastic Activity
10%
Gene Expression Profiling
9%
Hematopoietic Stem Cell
9%
Transplant Procedure
9%
Graft-Versus-Host Disease
9%
Cytotoxicity
8%
Leukemia Cell
8%
Lenalidomide
8%
CD20
8%
Acute Graft Versus Host Disease
8%
T Cell Receptor
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Tumor Volume
7%
Clonal Evolution
7%
Lymphocyte
7%
Tumor Cell
6%
Mitochondrial Respiration
6%
Pemphigus vulgaris
6%
Bispecific Antibody
6%
Ecalectin
6%
Drug Megadose
6%
Isoetarine
6%
Hematopoietic Stem Cell Transplantation
6%
Blood Plasma
5%
Neutrophil
5%
Monospecific Antibody
5%
Leukocyte Count
5%
Cell Membrane
5%
Conditioning
5%
M2 Macrophages
5%
Cyclophosphamide
5%
Keyphrases
Acute Myeloid Leukemia
59%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Overall Survival
21%
Intensive Chemotherapy
19%
Older Patients
17%
Decitabine
16%
Netherlands
15%
Leukemia Patients
12%
Hazard Ratio
12%
Confidence Interval
12%
Improved Outcomes
11%
Leukemia Risk
10%
Health-related Quality of Life
10%
Clonal Hematopoiesis
10%
Myelodysplastic Syndrome
9%
Anemia
9%
Lenalidomide
8%
Angioimmunoblastic T-cell Lymphoma
8%
Chemotherapy
8%
Rituximab
7%
High Risk
7%
Cytopenia
7%
High-risk Myelodysplastic Syndrome
7%
Cytarabine
7%
Azacitidine
6%
Non-myeloablative Transplantation
6%
Nonmyeloablative
6%
Pemphigus Vulgaris
6%
High-risk MDS
6%
Comorbidity
6%
Treatment Outcome
6%
Ara-C
6%
Induction Chemotherapy
6%
Graft-versus-host Disease (GvHD)
5%
Hematopoietic Cell Transplantation
5%
Aging
5%
Cancer Registry
5%
B Cells
5%
Leukemia
5%
Prospective Randomized Trial
5%
Peripheral T-cell Lymphoma
5%
